Market Outlook
By 2032, the U.S. Endourology Devices Market is expected to reach approximately USD 4.35 billion, expanding at a CAGR of 8.27% during the forecast period 2027–2032. The market stood at USD 2.70 billion in 2026, following historical values of approximately USD 2.15 billion in 2023, USD 2.31 billion in 2024, and USD 2.49 billion in 2025. Values in this report are expressed in USD billions.
The U.S. endourology devices industry sits at the convergence of minimally invasive urological surgery, chronic stone disease management, urologic oncology, ambulatory surgical economics, and advanced photonic energy delivery. Demand is propelled by an immense and accelerating clinical burden of urolithiasis, benign prostatic hyperplasia, non-muscle invasive bladder cancer, upper tract urothelial carcinoma, and urinary tract strictures. In 2024, approximately 11.2% of adult men and 7.1% of adult women in the United States reported a history of kidney stone formation, continuing an upward epidemiological trajectory linked to metabolic syndrome, shifting dietary patterns, rising obesity rates, and ambient climate warming across prominent population corridors. Urolithiasis alone accounted for more than 1.85 million emergency department presentations in 2025 and generated approximately USD 12.40 billion in direct and indirect annual medical expenditures. This heavy clinical throughput drives continuous, non-cyclical utilization of flexible digital ureteroscopes, holmium:YAG and thulium fiber surgical lasers, stone retrieval baskets, ureteral access sheaths, steerable guidewires, and double-J stents.
Benign prostatic hyperplasia represents an equally critical, demographically protected volume engine for endourological instrumentation. Diagnosed benign prostatic hyperplasia prevalence among American men aged 60 and older surpassed 53% in 2025, expanding past 70% in men aged 70 and older. The surgical management of lower urinary tract symptoms secondary to benign prostatic obstruction generates immense procedural volumes for resectoscopes, bipolar plasma vaporization loops, laser enucleation fibers, tissue morcellators, and high-volume fluid irrigation manifolds. Concurrently, bladder cancer remains the sixth most frequently diagnosed malignancy in the United States, recording approximately 84,200 new diagnoses in 2025. Because non-muscle invasive bladder cancer requires lifelong endourological surveillance and repeated transurethral interventions, it sustains durable baseline demand for diagnostic and therapeutic cystoscopes, photodynamic blue-light visualization platforms, and endoscopic biopsy instrumentation.
The market is simultaneously undergoing a profound structural transition from capital-intensive, reusable endoscopic hardware toward sterile, single-use disposable scopes and intelligent fluid-management consumables. This migration is transforming hospital capital allocation and surgical workflow economics. Single-use digital flexible ureteroscopes and cystoscopes eradicate the risk of cross-contamination from multi-drug resistant pathogens, completely eliminate off-site central sterile processing delays, and release health systems from crippling per-procedure scope repair budgets. Manufacturers that successfully integrate high-definition CMOS digital sensor tips with high-frequency thulium laser lithotripsy platforms, intrarenal pressure-sensing access sheaths, and biocompatible accessories are capturing substantial competitive advantages over legacy suppliers selling commoditized, standalone hardware.
Historically, the market expanded as surgical facilities rapidly eliminated elective case backlogs, updated aging holmium generator fleets, and shifted uncomplicated endourological interventions into lower-cost outpatient environments. From 2027 through 2032, market momentum will increasingly hinge on the broad penetration of single-use endoscopes across ambulatory surgery centers, the integration of artificial intelligence for intraoperative stone localization and fragmentation analysis, the standard adoption of active suction and real-time intrarenal pressure monitoring, and enterprise contracting models that blend capital placement with high-margin disposable commitments.
Introduction
According to the U.S. Endourology Devices Market Report, endourology occupies a uniquely strategic position within the domestic medical device sector due to its high procedural cadence, mandatory device utilization per encounter, and expansive continuum of care spanning diagnostic clinics, ambulatory surgery centers, and inpatient hospital surgical suites. Unlike surgical subspecialties where medical management can indefinitely substitute for procedural intervention, obstructing urinary calculi and symptomatic bladder outlet obstruction mandate mechanical, laser, or endoscopic resolution to prevent irreversible renal parenchyma damage, recurrent pyelonephritis, and life-threatening urosepsis. Consequently, endourological devices exhibit exceptional procedural resiliency across economic cycles.
The structural composition of the U.S. market divides into high-acuity surgical capital equipment and high-velocity recurring consumables. Accessories and consumables formed the largest revenue segment, representing approximately 48.4% of total domestic market value in 2025. Every therapeutic ureteroscopy, percutaneous nephrolithotomy, or transurethral resection requires an orchestrated ensemble of single-use disposables, including hydrophilically coated guidewires, multi-wire nitinol stone retrieval baskets, dual-lumen ureteral access sheaths, and indwelling drainage stents. The predictable, per-case consumption of these accessories provides medical device manufacturers with recurring cash flows that buffer capital procurement volatility.
Hospitals and integrated health systems remain the primary capital spenders, capturing roughly 57.8% of total device revenue under broad end-user categories in 2025. Hospital operating rooms require multi-specialty imaging towers, high-wattage holmium:YAG laser generators with advanced pulse-shaping capabilities, dedicated percutaneous nephrolithotomy fluoroscopic suites, and comprehensive reusable endoscope inventories to manage complex anatomical anomalies and high-acuity stone burdens. However, the operational economics of hospital urology departments are under unprecedented scrutiny. Urologic surgeons operate under aggressive operating room turnover mandates, while infection-prevention committees enforce rigorous audits of endoscope reprocessing workflows following repeated federal advisories regarding pathogen transmission via complex lumened devices.
Ambulatory surgery centers represent the fastest-expanding care setting within the endourology ecosystem. Driven by payer-mandated site-of-care optimization, favorable Medicare ambulatory payment classifications, and physician-investor alignment, uncomplicated flexible ureteroscopy, retrograde intrarenal surgery, diagnostic cystoscopy, and transurethral prostate therapies have migrated swiftly into outpatient facilities. Ambulatory centers operate under strict margin parameters, favoring technologies that eliminate capital maintenance liabilities, streamline room setup times, and provide predictable per-procedure supply costs. The rapid adoption of single-use flexible ureteroscopes, lightweight thulium fiber lasers, and bundled consumable kits directly addresses the clinical workflow requirements of the outpatient surgical model.
From a regulatory and reimbursement standpoint, endourological device manufacturers operate within an evolving matrix overseen by the Centers for Medicare & Medicaid Services and private commercial payers. The Medicare outpatient prospective payment system and physician fee schedule dictate facility reimbursements for common Current Procedural Terminology codes covering cystourethroscopy, lithotripsy, and ureteral catheterization. Concurrently, hospital value-analysis committees increasingly condition device formulary acceptance on holistic health-economic dossiers proving reductions in operating room duration, elimination of secondary interventions for residual stone fragments, and avoidance of postoperative sepsis readmissions. Between 2027 and 2032, market supremacy will belong to manufacturers that deliver integrated, closed-loop procedural solutions that harmonize digital optics, laser energy modulation, real-time hemodynamic safety monitoring, and seamless clinical documentation.
Key Market Drivers: What’s Fueling the U.S. Endourology Devices Market Boom?
The primary catalyst driving the domestic market is the sustained escalation in urolithiasis prevalence and recurrence across the United States. Epidemiological tracking confirms that approximately 1 in 10 Americans will suffer from a urinary tract calculus during their lifetime, with five-year recurrence rates approaching 50% without targeted metabolic intervention. Dietary patterns characterized by excessive sodium intake, high animal protein consumption, and inadequate hydration, compounded by the rising prevalence of type 2 diabetes and hypertension, have expanded stone disease far beyond historical demographics. Furthermore, geographic shifts in climate patterns have exacerbated heat-related dehydration, fueling what urological researchers describe as an expanding “Stone Belt.” In 2025, approximately 3.45 million surgical and outpatient interventions were performed across the country to diagnose, fragment, extract, or bypass urinary calculi, generating an enormous, non-deferrable requirement for advanced endourological devices.
A second major growth driver is the rapid, structural migration from reusable flexible endoscopes to single-use disposable architectures. Reusable flexible ureteroscopes feature complex internal working channels, delicate steering wire mechanisms, and fragile fiber-optic or electronic digital cables that are highly susceptible to mechanical fatigue and thermal damage from laser back-burn. Industry data indicates that reusable flexible ureteroscopes historically require major repairs after an average of only 12 to 15 surgical procedures, resulting in per-repair costs exceeding USD 1,600 to USD 2,200. When accounting for reprocessing labor, chemical sterilization agents, scope downtime, and the capital expense of maintaining large replacement scope reserves, single-use digital ureteroscopes present an undeniable economic justification for both community hospitals and ambulatory surgery centers. By providing guaranteed distal deflection, pristine optical clarity, and zero contamination risk for every surgical encounter, disposable scopes have permanently disrupted hospital procurement strategy.
A third driver is the rapid technological evolution and commercial adoption of high-frequency surgical laser platforms, specifically advanced pulse-modulated holmium:YAG and thulium fiber lasers. Traditional stone fragmentation required high pulse energies that frequently caused retropulsion, propelling the stone deep into inaccessible calyces and necessitating time-consuming basket retrieval. Modern thulium fiber laser systems operate at extreme frequencies up to 2400 Hz and utilize microscopic optical fibers down to 150 microns in core diameter, allowing surgeons to execute ultra-fine stone “dusting.” This technique pulverizes dense calcium oxalate monohydrate and brushite stones into microscopic particulates that spontaneously wash out during urination, dramatically shortening operative times and reducing the requirement for secondary stone retrieval instrumentation.
The fourth foundational driver is the dramatic transition of urological surgical procedures into the ambulatory surgery center setting. Medicare payment updates and commercial health plan prior-authorization mandates have steadily incentivized the transfer of low-to-moderate acuity endourological procedures out of high-cost inpatient hospital operating rooms. Ambulatory surgery centers now perform more than 40% of all elective ureteroscopy and cystoscopy procedures nationwide. Because ambulatory centers prioritize rapid turnover times, low overhead, and predictable operational expenditures, they heavily favor compact, air-cooled laser generators that operate on standard wall outlets, alongside all-in-one single-use scope and consumable packages that simplify inventory management and billing reconciliation.
A fifth driver is the heightened institutional focus on intrarenal pressure management and the prevention of post-procedural urosepsis. During retrograde intrarenal surgery, continuous fluid irrigation is essential to maintain endoscopic visibility against bleeding and particulate dust. However, continuous fluid inflow can quickly elevate intrarenal pressure above 30 to 40 mmHg, surpassing the threshold for pyelovenous and pyelolymphatic backflow. This backflow drives bacteria and endotoxins directly into the systemic circulation, causing severe postoperative infectious complications that carry substantial financial penalties under hospital value-based purchasing programs. The market introduction of intelligent ureteral access sheaths equipped with distal micro-sensors that actively measure pressure and incorporate continuous aspiration channels has redefined surgical safety standards, catalyzing immediate adoption across academic and tertiary institutions.
Finally, the expanding volume of benign prostatic hyperplasia interventions driven by an aging male demographic provides an indispensable volume foundation. As surgical paradigms transition from traditional monopolar transurethral resection of the prostate toward minimally invasive, tissue-preserving enucleation and vaporization techniques, demand has surged for high-powered surgical lasers, bipolar resectoscope systems, tissue morcellators, and specialized prostatic access devices. The intersection of these demographic realities with disruptive product innovations ensures an exceptionally durable multi-year growth trajectory for the domestic market.
Innovation in Focus: How Manufacturers Are Raising the Bar?
Innovation within the U.S. endourology devices market has advanced beyond incremental hardware refinements to encompass comprehensive, digitally integrated procedural ecosystems that elevate clinical efficacy, reduce procedural duration, and safeguard patient physiology. Manufacturers are dedicating extensive research and development resources to solve the historical compromises of endourology: balancing optical miniaturization against working channel capacity, maximizing laser dusting power without inducing thermal tissue damage, and maintaining pristine visual fields without exposing the renal pelvis to dangerously elevated intrarenal pressures.
Single-use digital visualization technology has achieved technological parity with, and in several performance vectors exceeded, legacy reusable systems. Modern single-use flexible ureteroscopes incorporate advanced complementary metal-oxide-semiconductor sensors positioned directly at the distal scope tip, providing full 1080p high-definition imagery and ultra-wide dynamic range that compensates instantly for variable intraoperative lighting. Distal tip outer diameters have shrunk below 7.5 French while preserving generous 3.6 French inner working channels. This miniaturization allows the scope to deflect up to 275 degrees in both directions even with a laser fiber or stone basket loaded, granting unprecedented surgical access to lower pole renal calyces that previously challenged even veteran endourologists. Furthermore, manufacturers are embedding integrated illumination modules that eliminate external light cables, drastically reducing clutter around the sterile field.
Laser technology has entered a revolutionary phase marked by the clinical deployment of thulium fiber lasers and advanced pulse-shaping holmium systems. Thulium fiber lasers utilize diode-pumped, silica-doped fibers to generate a continuous-wave beam that is sliced into pulses at a wavelength of 1940 nm. This wavelength aligns precisely with the peak absorption of liquid water, resulting in an absorption coefficient four times higher than that of holmium:YAG lasers. Consequently, thulium fiber lasers create microscopic cavitation bubbles with minimal acoustic shock waves, allowing surgeons to dust stones into powder with virtually zero retropulsion. Concurrently, leading holmium manufacturers have introduced proprietary double-pulse modulation technologies that separate the laser pulse into an initial low-energy bubble-initiating phase followed by a high-energy fragmentation phase, dramatically improving energy transmission across the fluid medium.
The most transformative engineering frontier in endourology is the commercialization of active pressure-monitoring and fluid-aspiration platforms. Next-generation ureteral access sheaths now feature embedded pressure micro-transducers that interface directly with digital fluid management pumps. When intrarenal pressure approaches clinically dangerous limits, the intelligent pump automatically modulates inflow rates while engaging active negative-pressure suction through the sheath channel. This continuous, balanced aspiration removes fine stone dust, blood clots, and warm irrigation fluid simultaneously, maintaining immaculate endoscopic visibility, preventing hyperthermia in the collecting system, and keeping intrarenal pressure safely below physiological backflow limits. This technology represents a profound clinical evolution, shifting the access sheath from a passive conduit into an active hemodynamic safeguard.
Material science has elevated stone retrieval baskets from rudimentary wire snares to advanced multi-dimensional geometry tools. Modern extractors utilize biocompatible nitinol alloys engineered with customized thermal shape-memory profiles. Manufacturers have perfected tip-less basket designs that permit direct caliceal exploration and stone capture against the urothelial floor without causing mucosal abrasion or bleeding. Ultra-fine wire diameters down to 1.3 French minimize deflection resistance inside fully articulated flexible scopes, preserving continuous fluid irrigation and surgical visibility during complex stone retrieval in tortuous upper tract anatomies.
Artificial intelligence and computer vision software are beginning to transform intraoperative surgical navigation and documentation. New endoscopic video platforms leverage edge-computing algorithms to analyze digital scope video feeds in real time, automatically segmenting stone margins, calculating stone volume, and predicting stone mineral composition based on light absorption spectra. These systems provide the operating surgeon with objective, visual confirmation of fragment size thresholds, ensuring that only clinically insignificant fragments under 1.5 millimeters are left for spontaneous passage. By streamlining documentation and delivering objective stone-free verification, AI software integration is bridging the gap between operative technique and quantifiable surgical outcomes.
Segmentation Insights
The U.S. Endourology Devices Market is segmented on the basis of product type, usability modality, disease indication, technology type, procedure type, and end user.
- By Product Type
The U.S. endourology devices market is segmented by product type into accessories and consumables, endoscopes, and lithotripsy devices.
Accessories and Consumables
Accessories and consumables represent the largest product segment, capturing approximately 48.4% of total domestic market value in 2025. This segment generated USD 1.04 billion in 2023, USD 1.12 billion in 2024, USD 1.21 billion in 2025, and USD 1.31 billion in 2026. By 2032, this product category is projected to reach approximately USD 2.12 billion, advancing at an assertive CAGR of 8.35% from 2027 to 2032.
The dominance of accessories and consumables stems directly from the fact that every single endourological intervention—whether a simple outpatient diagnostic cystoscopy or an intricate percutaneous nephrolithotomy—demands a non-negotiable array of sterile, single-use disposable devices. The sub-segment includes ureteral access sheaths, stone retrieval baskets and graspers, ureteral stents, steerable guidewires, dilation balloons and catheters, and biopsy forceps and resection loops.
Ureteral access sheaths have experienced substantial value growth, moving from passive fluoropolymer tubes to high-performance composite sheaths equipped with kink-resistant wire-braided bodies, hydrophilic lubricious coatings, and integrated pressure sensors with active suction capabilities. Stone retrieval baskets have expanded dynamically, propelled by the widespread adoption of multi-wire nitinol designs that provide high radial expansion force, zero-tip caliceal engagement, and micro-wire footprints that do not choke scope working channels.
Ureteral stents represent another massive, high-volume recurring revenue pool. Driven by procedural requirements to relieve post-lithotripsy edema and preserve renal drainage, millions of double-J stents are placed annually in the United States. Innovation in this space focuses on biocompatible silicone and polyurethane formulations engineered with specialized hydrophilic or heparin coatings to resist biofilm formation and bacterial encrustation. Furthermore, the commercial emergence of magnetic-tip and biodegradable stents that bypass the necessity of a secondary cystoscopic stent removal procedure is creating substantial premiumization within the consumables portfolio.
Guidewires, representing the indispensable safety line for upper tract access, continue to command robust recurring volume, characterized by advanced nitinol core architectures, tungsten radiopaque tips, and torque-stable hydrophilic jackets that navigate severe ureteral tortuosity without creating false passages.
Endoscopes
Endoscopes comprise the critical visual visualization hardware of endourology, including rigid and semi-rigid ureteroscopes, flexible ureteroscopes, rigid cystoscopes, flexible cystoscopes, and nephroscopes and resectoscopes. The endoscopes segment generated USD 0.65 billion in 2023, USD 0.70 billion in 2024, USD 0.75 billion in 2025, and USD 0.81 billion in 2026. By 2032, endoscope revenue in the United States is forecast to reach approximately USD 1.31 billion, expanding at a CAGR of 8.33% over the forecast period.
Flexible digital ureteroscopes form the highest-value sub-segment within endoscopic hardware. These instruments are vital for navigating the complex anatomy of the ureter, renal pelvis, and minor renal calyces. The market has been reshaped by the rapid transition from fiber-optic bundles to chip-on-the-tip CMOS digital architectures, providing superior optical resolution, wide-angle illumination, and robust deflection mechanics.
Cystoscopes generate the highest procedural unit volumes within endoscopes, serving as the frontline workhorse across both hospital surgical departments and private outpatient urology clinics. Rigid cystoscopes retain clinical value for heavy transurethral resections of bladder tumors and complex bladder stone manipulations due to their large working channels, exceptional fluid inflow dynamics, and indestructible durability. Conversely, flexible cystoscopes dominate diagnostic evaluations, stent removals, and hematuria workups, offering maximum patient comfort under local anesthesia.
Nephroscopes, designed with large working channels for rigid ultrasonic or pneumatic lithotripters, sustain steady demand within percutaneous nephrolithotomy workflows, while resectoscopes represent the core surgical instrument for transurethral resection and enucleation of the prostate.
Lithotripsy Devices
Lithotripsy devices comprise the energy-emitting systems utilized to disintegrate, fragment, and pulverize urinary tract calculi and resect soft tissue. This segment includes holmium:YAG laser systems, thulium fiber laser systems, intracorporeal pneumatic and ultrasonic lithotripters, and extracorporeal shock wave lithotripsy systems. Domestic lithotripsy device revenue stood at USD 0.46 billion in 2023, USD 0.49 billion in 2024, USD 0.53 billion in 2025, and USD 0.58 billion in 2026. By 2032, this segment will reach approximately USD 0.92 billion, recording a CAGR of 8.00% between 2027 and 2032.
Laser lithotripsy systems capture the vast majority of category revenue, accounting for roughly 71.3% of the lithotripsy segment in 2025. Holmium:YAG lasers remain a cornerstone technology across U.S. hospital operating suites, particularly high-power generators delivering up to 120 watts with advanced pulse modulation capabilities that alter the vapor bubble dynamics to eliminate stone retropulsion. However, thulium fiber lasers represent the fastest-growing technology within the lithotripsy hardware space. Operating at a wavelength of 1940 nm, thulium systems achieve exceptional dusting efficacy at micro-joule pulse energies and extreme repetition frequencies, allowing rapid stone pulverization through fibers as small as 150 microns.
Intracorporeal pneumatic and ultrasonic lithotripters maintain critical roles in percutaneous nephrolithotomy, where large, dense staghorn calculi require simultaneous high-energy acoustic shock disintegration and active suction evacuation.
Conversely, extracorporeal shock wave lithotripsy systems continue to experience flat-to-declining procedural share, as lower stone-free rates and high retreatment frequencies push clinicians decisively toward definitive endoscopic ureteroscopy.
- By Usability Modality
The market is segmented on the basis of usability modality into single-use and disposable devices, and reusable systems and instruments.
Single-Use and Disposable Devices
The single-use and disposable endourology devices segment generated USD 1.35 billion in 2023, USD 1.47 billion in 2024, USD 1.60 billion in 2025, and USD 1.76 billion in 2026. Projecting forward, this segment will surge to approximately USD 2.95 billion by 2032, exhibiting a market-leading CAGR of 9.00% during 2027–2032.
The extraordinary growth of this segment reflects the ongoing displacement of traditional reusable scopes alongside the non-negotiable disposable nature of accessories. Single-use flexible ureteroscopes and cystoscopes are the primary growth engines of this modality. By utilizing cost-effective CMOS imaging sensors, injection-molded polymers, and automated assembly, manufacturers have driven production costs down to levels that allow attractive commercial pricing per unit.
The commercial justification for single-use devices is rooted in clinical workflow and risk mitigation. Reusable endoscopes require high-level chemical disinfection or low-temperature sterilization, taking scopes out of service for hours, consuming valuable sterile processing technician time, and exposing staff to hazardous chemical vapors. More critically, reusable scopes suffer progressive degradation with every use, leading to reduced tip articulation, optical dimming, and catastrophic intraoperative mechanical failures. Single-use scopes eliminate these liabilities, ensuring that the operating surgeon receives an instrument with factory-pristine optical clarity, maximum deflection angles, and zero residual bioburden. For high-throughput ambulatory surgery centers, single-use scopes eliminate capital depreciation schedules and convert fixed service overhead into variable, directly billable per-case costs.
Reusable Systems and Instruments
The reusable systems and instruments segment generated USD 0.80 billion in 2023, USD 0.84 billion in 2024, USD 0.89 billion in 2025, and USD 0.94 billion in 2026. By 2032, this segment is forecast to reach approximately USD 1.40 billion, expanding at a CAGR of 6.85% from 2027 to 2032.
While losing relative market share to disposable alternatives, the reusable segment remains an essential and highly profitable foundation of the endourology landscape. This category includes high-capital infrastructure such as laser generators, video processing and illumination towers, fluid management control units, extracorporeal shock wave lithotripters, and rigid optical instruments.
Rigid and semi-rigid endoscopes—including metal-sheathed nephroscopes, diagnostic resectoscopes, and rigid cystoscopes—continue to maintain robust positions across hospital systems. These instruments feature rod-lens optical systems that deliver exceptional light transmission, wide fields of view, and large working channels that cannot be economically replicated in single-use formats. Furthermore, rigid stainless-steel instruments exhibit extraordinary lifespans, enduring hundreds of standard steam autoclave cycles with minimal maintenance costs.
For large academic medical centers with dedicated central sterile processing infrastructures and multi-suite urology departments, high-end reusable flexible endoscopes supported by comprehensive multi-year service and exchange contracts still retain selective financial viability. Manufacturers of reusable systems compete fiercely by establishing enterprise-level lifecycle agreements that bundle equipment leasing, preventive maintenance, expedited emergency repairs, and planned technology upgrades into standardized monthly payments.
- By Disease Indication
The U.S. endourology devices market is segmented by disease indication into urolithiasis, benign prostatic hyperplasia, urothelial carcinoma and bladder cancer, and urinary strictures and other indications.
Urolithiasis
Urolithiasis constitutes the largest disease indication for endourological instrumentation, representing approximately 56.2% of overall domestic market demand in 2025. The segment generated USD 1.21 billion in 2023, USD 1.30 billion in 2024, USD 1.40 billion in 2025, and USD 1.52 billion in 2026. By 2032, urolithiasis device revenue is projected to reach approximately USD 2.47 billion, expanding at a CAGR of 8.44% between 2027 and 2032.
This clinical category encompasses the diagnosis, fragmentation, and extraction of stones throughout the urinary tract, sub-divided into nephrolithiasis (renal calculi), ureterolithiasis (ureteral calculi), and cystolithiasis (bladder calculi). Nephrolithiasis represents the largest and most technologically intensive component, as stones situated within the lower and middle renal calyces demand high-deflection flexible digital ureteroscopes, multi-frequency laser fibers, and active pressure-regulated access sheaths. Ureterolithiasis cases, which frequently present as acute surgical emergencies due to painful ureteral obstruction and secondary hydronephrosis, consume vast quantities of semi-rigid ureteroscopes, holmium and thulium laser fibers, nitinol stone baskets, and double-J stents. Cystolithiasis, often secondary to chronic urinary retention from prostatic enlargement, utilizes high-impact pneumatic lithotripters or mechanical stone crushers through large-bore resectoscope sheaths.
The relentless expansion of this segment is underpinned by persistent metabolic factors, rising obesity rates, high dietary animal protein and sodium consumption, and the expanding geographic reach of the U.S. “Stone Belt.”
Benign Prostatic Hyperplasia
Benign prostatic hyperplasia represents the second largest disease indication, capturing approximately 23.3% of market revenue in 2025. The segment generated USD 0.50 billion in 2023, USD 0.54 billion in 2024, USD 0.58 billion in 2025, and USD 0.63 billion in 2026. Moving toward 2032, benign prostatic hyperplasia device spending is expected to reach approximately USD 1.02 billion, growing at an assertive CAGR of 8.35% from 2027 to 2032.
The clinical necessity of surgical intervention for benign prostatic obstruction accelerates sharply with advancing age, as millions of American men experience progressive urinary hesitancy, poor stream, nocturia, and urinary retention unresponsive to pharmacological alpha-blockers and 5-alpha reductase inhibitors. The endourological management of this condition encompasses several distinct procedural modalities, each supported by specialized instrumentation. Transurethral resection of the prostate, long regarded as the surgical benchmark, continues to generate substantial recurring revenue for continuous-flow resectoscopes and bipolar plasma cutting and vaporization loops. Concurrently, minimally invasive laser therapies have captured major procedural volume. Holmium laser enucleation of the prostate (HoLEP) and thulium laser enucleation of the prostate (ThuLEP) utilize high-power laser energy to anatomically enucleate large prostatic adenomas, requiring specialized end-firing laser fibers, high-definition continuous-flow endoscopes, and mechanical morcellators to morcellate and evacuate tissue from the bladder. Furthermore, photoselective vaporization of the prostate (PVP) utilizing green-light laser platforms continues to command strong outpatient surgical volumes.
Urothelial Carcinoma and Bladder Cancer
The urothelial carcinoma and bladder cancer segment accounted for USD 0.30 billion in 2023, USD 0.32 billion in 2024, USD 0.35 billion in 2025, and USD 0.38 billion in 2026. The segment is projected to achieve approximately USD 0.60 billion by 2032, expanding at a CAGR of 7.91% between 2027 and 2032.
Bladder cancer is characterized by exceptional lifetime surveillance intensity. Approximately 75% of newly diagnosed bladder cancers present as non-muscle invasive bladder cancer, a malignancy associated with high recurrence rates exceeding 60% within five years. Consequently, clinical guidelines mandate that post-resection patients undergo surveillance cystoscopy every three to six months for several years. This rigorous protocol produces massive, continuous demand for flexible diagnostic cystoscopes, high-resolution video processors, and sterile single-use biopsy forceps across outpatient urology clinics. Within the hospital operating room, therapeutic transurethral resection of bladder tumor (TURBT) relies on specialized bipolar resectoscope systems and cold-cup biopsy forceps. Growth in this segment is strongly bolstered by advanced diagnostic visualization technologies, such as blue-light photodynamic diagnostic cystoscopy utilizing optical imaging agents and narrow-band imaging, which enhance the contrast of hypervascular malignant urothelial lesions and occult carcinoma in situ. Upper tract urothelial carcinoma, while less prevalent, drives demand for small-caliber flexible digital ureteroscopes, specialized biopsy brushes, and laser ablation fibers.
Urinary Strictures and Other Indications
Urinary strictures and other endourological indications generated USD 0.14 billion in 2023, USD 0.15 billion in 2024, USD 0.16 billion in 2025, and USD 0.17 billion in 2026. By 2032, this diverse clinical segment will reach approximately USD 0.26 billion, recording a CAGR of 7.33% over the forecast period.
This segment encompasses the surgical management of urethral strictures, ureteral strictures, pelviureteric junction obstruction, and post-radiation fibrotic stenosis. Urethral stricture management sustains recurring utilization of optical urethrotomes, cold-knife blades, and high-pressure balloon dilation catheters designed to expand dense collagenous scar tissue. Ureteral strictures and pelviureteric junction obstructions often require endoscopic endopyelotomy using specialized cutting balloon catheters or holmium laser fibers, followed by prolonged drainage with large-caliber endopyelotomy stents. While patient numbers in these sub-categories are smaller than in urolithiasis or benign prostatic hyperplasia, the surgical interventions are technologically complex, demanding high-pressure fluid delivery, precision laser incision, and customized stent architectures that command premium price points.
- By Technology Type
The market is segmented on the basis of technology type into high-definition digital and chip-on-the-tip endoscopy, advanced laser energy delivery, intelligent pressure-sensing and active aspiration platforms, and fiber-optic endoscopy.
High-Definition Digital and Chip-on-the-Tip Endoscopy
The high-definition digital and chip-on-the-tip endoscopy segment generated USD 0.95 billion in 2023, USD 1.03 billion in 2024, USD 1.12 billion in 2025, and USD 1.23 billion in 2026. By 2032, this technology segment is projected to reach approximately USD 2.05 billion, delivering a robust CAGR of 8.89% from 2027 to 2032.
Digital chip-on-the-tip technology represents the dominant imaging paradigm in modern endourology, having effectively replaced legacy fiber-optic bundles in both premium reusable and disposable instruments. By positioning a microscopic CMOS or CCD image sensor directly at the distal tip of the endoscope alongside high-intensity LED light sources, this architecture completely eliminates the fragility, pixelation, and progressive fiber breakage characteristic of older scopes. The technology delivers true 1080p and emerging 4K resolution directly to surgical monitors, providing exceptional depth of field, color fidelity, and contrast resolution. This visual precision is vital for identifying subtle mucosal pathology in bladder and ureteral malignancies, visualizing microscopic stone fragments, and navigating complex caliceal infundibula. The continuous cost reduction of micro-CMOS sensors has been the primary technological enabler of the single-use flexible ureteroscope revolution, allowing high-performance imaging to be deployed in disposable formats.
Advanced Laser Energy Delivery
Advanced laser energy delivery systems generated USD 0.48 billion in 2023, USD 0.52 billion in 2024, USD 0.56 billion in 2025, and USD 0.61 billion in 2026. The segment is forecast to achieve approximately USD 0.99 billion by 2032, expanding at a CAGR of 8.41% over the forecast period.
This segment includes sophisticated thulium fiber lasers, dual-pulse modulation holmium:YAG generators, and high-energy green-light vaporization systems. The technological evolution within this category centers on optimizing pulse duration, peak power, and repetition frequency to maximize stone comminution while minimizing retropulsion and thermal collateral tissue injury. Advanced holmium systems utilize proprietary pulse-shaping algorithms that fire an initial low-energy pulse to displace water and form a vapor channel, immediately followed by the primary therapeutic pulse, allowing surgical energy to be delivered directly to the calculus with minimal acoustic blast wave. Simultaneously, thulium fiber lasers have established a new performance benchmark for dusting lithotripsy, operating at four times the water absorption peak of holmium and reaching repetition rates up to 2400 Hz. These systems utilize thin, flexible fibers that do not compromise scope deflection, permitting rapid stone vaporization in tortuous anatomical locations.
Intelligent Pressure-Sensing and Active Aspiration Platforms
Intelligent pressure-sensing and active aspiration platforms accounted for USD 0.28 billion in 2023, USD 0.31 billion in 2024, USD 0.34 billion in 2025, and USD 0.38 billion in 2026. Moving toward 2032, this segment will reach approximately USD 0.68 billion, recording the fastest growth among technology segments with a CAGR of 10.20% between 2027 and 2032.
This rapidly expanding segment represents a paradigm shift in surgical safety during retrograde intrarenal surgery and percutaneous stone procedures. During endoscopic lithotripsy, continuous high-pressure fluid irrigation is required to clear dust and blood; however, unmonitored intrarenal pressures frequently exceed critical physiological thresholds, driving infected urine and endotoxins into the renal parenchyma and vascular system. Intelligent platforms resolve this danger by embedding micro-pressure transducers into the distal tip of ureteral access sheaths or dedicated intrarenal monitoring catheters. These sensors continuously relay real-time pressure data to an automated fluid control unit. When pressures reach dangerous levels, the system automatically attenuates inflow and engages active peristaltic suction through dedicated channels. This active aspiration simultaneously evacuates stone dust, eliminates thermal energy buildup from laser firing, and maintains low intrarenal pressures, practically eradicating the risk of post-procedural urosepsis and dramatically shortening operative duration.
Fiber-Optic Endoscopy
Fiber-optic endoscopy generated USD 0.44 billion in 2023, USD 0.45 billion in 2024, USD 0.47 billion in 2025, and USD 0.48 billion in 2026. The segment is projected to reach approximately USD 0.63 billion by 2032, advancing at a modest CAGR of 4.63% from 2027 to 2032.
Fiber-optic endoscopy represents a mature, gradually declining technology category within endourology. These instruments rely on coherent bundles of tens of thousands of microscopic optical glass fibers to transmit light from an external source to the surgical site and relay the optical image back to a proximal eyepiece or camera head. While historically revolutionary, fiber-optic scopes suffer from inherent physical vulnerabilities. Repeated extreme deflection cycles, mechanical stress during insertion through access sheaths, and stray laser strikes inevitably fracture individual glass fibers, producing permanent black pixel defects on the video display. Furthermore, fiber-optic scopes exhibit lower optical resolution, narrower dynamic range, and progressive image degradation compared to modern digital CMOS sensors. Nevertheless, fiber-optic instruments maintain presence within cost-sensitive community hospitals and smaller outpatient clinics where existing capital inventories are maintained until complete functional failure.
- By Procedure Type
The market is segmented on the basis of procedure type into retrograde intrarenal surgery and ureteroscopy, transurethral resection of the prostate and laser enucleation, transurethral resection of bladder tumor and diagnostic cystoscopy, and percutaneous nephrolithotomy.
Retrograde Intrarenal Surgery and Ureteroscopy
Retrograde intrarenal surgery and ureteroscopy represents the largest procedural segment, capturing approximately 42.6% of domestic endourological device revenue in 2025. The segment generated USD 0.92 billion in 2023, USD 0.99 billion in 2024, USD 1.06 billion in 2025, and USD 1.16 billion in 2026. By 2032, this procedure segment is forecast to reach approximately USD 1.90 billion, advancing at a CAGR of 8.58% during 2027–2032.
The dominance of retrograde intrarenal surgery and ureteroscopy is driven by its position as the definitive, first-line minimally invasive treatment for renal and ureteral stones up to 2 centimeters in diameter. Ureteroscopic interventions avoid any external surgical incisions, navigating instruments retrograde through the urethra, bladder, and ureter into the renal collecting system. The continuous refinement of flexible digital ureteroscopes, combined with ultra-fine thulium and holmium laser fibers and suction-enabled ureteral access sheaths, has dramatically expanded the clinical indications for retrograde intrarenal surgery, allowing surgeons to successfully treat complex multi-caliceal and lower-pole stones that previously required invasive percutaneous surgery. Every ureteroscopic procedure utilizes an extensive bill of materials, including single-use access sheaths, guidewires, laser fibers, nitinol retrieval baskets, and post-operative double-J stents, generating substantial per-case consumable revenue.
Transurethral Resection of the Prostate and Laser Enucleation
Transurethral resection of the prostate and laser enucleation procedures accounted for USD 0.52 billion in 2023, USD 0.56 billion in 2024, USD 0.60 billion in 2025, and USD 0.65 billion in 2026. By 2032, spending across this procedural segment is expected to reach approximately USD 1.04 billion, growing at a CAGR of 8.15% between 2027 and 2032.
This segment encompasses all endoscopic interventions designed to resect, enucleate, or vaporize obstructing prostatic tissue in men suffering from medically refractory benign prostatic hyperplasia. Monopolar and bipolar transurethral resection of the prostate remains a high-volume surgical staple across U.S. hospitals, generating steady demand for specialized resectoscope sheaths, continuous-flow passive and active working elements, and disposable cutting and coagulation loops. However, the procedural mix is shifting heavily toward anatomical laser enucleation techniques, primarily holmium laser enucleation of the prostate (HoLEP) and thulium laser enucleation of the prostate (ThuLEP). Laser enucleation provides superior outcomes for large prostates exceeding 80 grams, dramatically reducing intraoperative hemorrhage, catheterization duration, and hospital length of stay. These advanced procedures require high-power laser generators, specialized end-firing enucleation fibers, continuous irrigation sets, and mechanical tissue morcellators equipped with reciprocating blades to extract enucleated tissue fragments from the bladder.
Transurethral Resection of Bladder Tumor and Diagnostic Cystoscopy
Transurethral resection of bladder tumor and diagnostic cystoscopy generated USD 0.43 billion in 2023, USD 0.46 billion in 2024, USD 0.50 billion in 2025, and USD 0.54 billion in 2026. The segment is projected to achieve approximately USD 0.84 billion by 2032, recording a CAGR of 7.64% over the forecast period.
This procedural category represents the absolute volume backbone of outpatient urological practice and oncological operating room schedules. Diagnostic cystoscopy is performed millions of times annually across the United States to evaluate gross or microscopic hematuria, investigate chronic pelvic pain syndromes, monitor recurrent urinary tract infections, and execute mandatory oncological surveillance in patients treated for bladder cancer. The rapid migration of diagnostic cystoscopy into outpatient clinics has accelerated the utilization of single-use flexible cystoscopes, which eliminate scope reprocessing turnaround times and permit high-throughput clinical scheduling. For patients with identified bladder tumors, transurethral resection of bladder tumor serves as both the definitive diagnostic staging procedure and primary therapeutic resection. These operative interventions consume substantial volumes of rigid resectoscopes, bipolar resection loops, cold-cup biopsy forceps, fulguration electrodes, and advanced optical imaging agents that highlight malignant urothelium.
Percutaneous Nephrolithotomy
Percutaneous nephrolithotomy generated USD 0.28 billion in 2023, USD 0.30 billion in 2024, USD 0.33 billion in 2025, and USD 0.35 billion in 2026. Moving toward 2032, percutaneous nephrolithotomy device spending will reach approximately USD 0.57 billion, growing at a CAGR of 8.48% from 2027 to 2032.
Percutaneous nephrolithotomy remains the undisputed clinical gold standard for the treatment of large, complex, or staghorn renal calculi exceeding 2 centimeters in diameter, as well as stones resistant to shock wave or ureteroscopic fragmentation. The procedure involves establishing a direct percutaneous tract from the patient’s flank into the renal collecting system under fluoroscopic and ultrasound guidance. Once tract dilation is achieved using sequential fascial or balloon dilators, an operational nephroscope sheath is placed. The procedural workflow utilizes specialized rigid and flexible nephroscopes, high-impact pneumatic and ultrasonic lithotripters with integrated continuous suction, high-power holmium laser fibers, large-capacity stone grasping forceps, and post-operative nephrostomy drainage tubes. In recent years, the clinical emergence of “Mini-PCNL” and “Micro-PCNL” techniques utilizing ultra-miniaturized access tracts down to 12 to 16 French has expanded the procedural appeal, reducing parenchymal bleeding and permitting faster recovery times while maintaining exceptional stone-free clearance rates.
- By End User
The U.S. endourology devices market is segmented by end user into hospitals and integrated health systems, ambulatory surgery centers, and specialty urology clinics.
Hospitals and Integrated Health Systems
Hospitals and integrated health systems represent the largest end-user category, accounting for approximately 57.8% of total domestic device demand in 2025. This institutional segment generated USD 1.24 billion in 2023, USD 1.34 billion in 2024, USD 1.44 billion in 2025, and USD 1.56 billion in 2026. By 2032, hospital endourology purchasing is projected to reach approximately USD 2.45 billion, expanding at a CAGR of 7.82% between 2027 and 2032.
Hospitals maintain their revenue dominance because they handle the complete clinical spectrum of endourological acuity. Complex percutaneous nephrolithotomies, emergency interventions for infected obstructing calculi, major transurethral resections of extensive bladder tumors, and advanced laser enucleation procedures in patients with severe cardiopulmonary comorbidities are managed exclusively in hospital operating suites. Large integrated delivery networks execute centralized capital procurement for multi-facility operations, negotiating enterprise-level agreements that encompass capital imaging towers, high-power laser generators, dedicated lithotripsy suites, and standardized consumable formularies. Hospital procurement behavior is highly structured, overseen by multidisciplinary value-analysis committees comprising surgical leadership, biomedical engineering, infection prevention, materials management, and healthcare finance. While hospitals continue to support established reusable scope inventories, their purchasing patterns are shifting rapidly toward hybrid models that integrate single-use flexible scopes for emergency weekend cases, off-hour on-call procedures, and infectious isolation patients to prevent cross-contamination and eliminate expensive on-call reprocessing labor.
Ambulatory Surgery Centers
Ambulatory surgery centers represent the fastest-growing end-user segment within the domestic landscape, capturing approximately 28.5% of market value in 2025. ASC device spending reached USD 0.61 billion in 2023, USD 0.66 billion in 2024, USD 0.71 billion in 2025, and USD 0.78 billion in 2026. By 2032, this dynamic care setting is forecast to achieve approximately USD 1.35 billion, recording an industry-leading CAGR of 9.60% from 2027 to 2032.
The explosive growth of ambulatory surgery centers is underpinned by systemic macroeconomic shifts in U.S. healthcare delivery. Commercial payers and Medicare have steadily expanded the list of covered outpatient urological procedures, incentivizing the migration of elective retrograde intrarenal surgery, uncomplicated laser lithotripsy, and outpatient benign prostatic hyperplasia treatments into lower-cost ambulatory facilities. ASCs operate on lean staffing and rapid operating room turnover schedules, making them the ultimate early adopters of single-use, workflow-optimized medical devices. Single-use digital flexible ureteroscopes are exceptionally well-suited for the ASC environment, as they eliminate the capital expense of purchasing multiple backup scopes, eradicate central sterile processing bottlenecks, and eliminate unpredictable scope repair invoices that directly erode per-procedure operating margins. Furthermore, ASC administrators favor compact, multi-functional laser platforms that operate on standard electrical circuits and require minimal footprint in multi-use surgical suites. Device manufacturers that offer all-in-one procedural packs containing single-use scopes, access sheaths, guidewires, and baskets negotiate highly lucrative, high-volume contracts with national ASC management networks.
Specialty Urology Clinics
Specialty urology clinics and outpatient diagnostic practices generated USD 0.30 billion in 2023, USD 0.31 billion in 2024, USD 0.34 billion in 2025, and USD 0.36 billion in 2026. Moving toward 2032, device purchasing across this clinical setting will reach approximately USD 0.55 billion, expanding at a CAGR of 7.30% between 2027 and 2032.
Specialty urology clinics serve as the essential outpatient gateway for endourological care, executing high-volume diagnostic evaluations, disease surveillance, and minor outpatient interventions under local anesthesia. This setting drives massive procedural volumes for flexible diagnostic cystoscopy, surveillance of non-muscle invasive bladder cancer, initial hematuria workups, and post-operative double-J stent removals. Urology group practices prioritize patient throughput, rapid room turnover, and minimal patient discomfort. The adoption of single-use flexible cystoscopes is accelerating rapidly within this space, as smaller private practices frequently lack the complex sterilization autoclaves and dedicated personnel required to maintain high-throughput reusable scope reprocessing. By utilizing single-use digital cystoscopes with integrated LED illumination, clinic staff can complete procedures, digitally archive images into the practice electronic health record, and prepare the examination room for the next patient in minutes, significantly maximizing daily physician productivity.
Regional Insights: Where the Market is Growing Fastest
The U.S. Endourology Devices Market is geographically segmented into the South, West, Midwest, and Northeast. Regional market performance is governed by complex variations in stone disease epidemiology, demographic aging, climate-related stone formation risk, state-level hospital infrastructure, ambulatory surgery center penetration, and urological surgical specialist density. The South represents the largest and most procedurally dense commercial market, while the West is positioned for the most aggressive technology-driven expansion. The Midwest exhibits durable, high-volume procedural demand anchored by major clinical health systems, and the Northeast maintains intense, high-value demand centered around academic medical centers and advanced surgical oncological adoption.
South
The South represents the undisputed largest geographic market for endourology devices in the United States, generating USD 0.99 billion in 2023, USD 1.07 billion in 2024, USD 1.15 billion in 2025, and USD 1.25 billion in 2026. By 2032, the Southern endourology devices market is projected to reach approximately USD 2.05 billion, expanding at an authoritative CAGR of 8.59% from 2027 to 2032.
The dominance of the South is anchored in a unique intersection of epidemiological, climatological, and demographic factors. The region encompasses the geographic epicenter of the historic American “Stone Belt,” a broad territorial band stretching across the southeastern states where ambient temperatures are high and sunlight exposure triggers elevated cutaneous vitamin D synthesis, leading to hypercalciuria and concentrated urinary output. This environmental reality, combined with regional dietary patterns rich in sodium, iced tea, and animal proteins, elevates urolithiasis prevalence in the South to levels 30% to 50% higher than the national baseline. Furthermore, the South has experienced unprecedented population in-migration, characterized by an influx of retirees who dramatically expand the demographic pool susceptible to benign prostatic hyperplasia, bladder cancer, and recurrent stone disease.
Texas stands as the premier state-level market within the South and the entire nation, generating approximately USD 0.38 billion in endourology device revenue in 2025. With an adult population exceeding 23 million, Texas recorded more than 2.85 million adults with a confirmed clinical history of urinary calculi in 2025. The immense geographic expanse of Texas, coupled with extreme summer temperatures, generates relentless, year-round emergency department stone presentations. Massive integrated health networks in the Texas Medical Center in Houston, alongside sophisticated healthcare systems across Dallas-Fort Worth, Austin, and San Antonio, support massive endourological surgical suites. The state has also witnessed aggressive expansion of physician-owned ambulatory surgery centers, which are pioneering high-volume single-use flexible ureteroscopy and thulium fiber laser adoption to manage high procedural throughput.
Florida represents the second largest commercial powerhouse in the South, accounting for approximately USD 0.32 billion in endourology device demand in 2025. Florida possesses the highest proportion of elderly residents of any major state, with individuals aged 65 and older representing more than 21% of its population. This demographic profile produces extraordinary clinical utilization for benign prostatic hyperplasia and bladder cancer devices. Florida urologists perform massive volumes of transurethral resections, holmium laser enucleation of the prostate, and photoselective prostate vaporizations to treat lower urinary tract symptoms, while lifelong cystoscopic bladder cancer surveillance represents a daily clinical staple across hundreds of outpatient clinics. Furthermore, Florida’s subtropical climate fuels an enormous baseline stone burden, driving continuous procurement of double-J stents, access sheaths, and single-use digital cystoscopes.
North Carolina, Georgia, and Virginia represent vital, high-growth sub-markets within the South. North Carolina generated approximately USD 0.14 billion in endourology device revenue in 2025, supported by more than 1.15 million adults with stone disease and prominent academic clinical systems in the Research Triangle and Charlotte. Georgia recorded approximately USD 0.13 billion in endourology device sales in 2025, with Atlanta serving as a major regional referral hub for complex percutaneous nephrolithotomy and advanced laser lithotripsy. Virginia added another USD 0.11 billion in 2025, driven by sophisticated health systems serving the dense Northern Virginia and Hampton Roads corridors. Tennessee, Louisiana, Alabama, and South Carolina contribute massive, non-cyclical stone volume, though healthcare delivery in these states often involves treating advanced, neglected stone disease in rural populations, necessitating extensive utilization of percutaneous nephroscopes and large-diameter stone extraction instrumentation.
The strategic challenge for medical device manufacturers in the South is managing high product distribution volumes across geographically dispersed healthcare networks. While metropolitan centers demand cutting-edge digital visualization and smart aspiration technologies, rural community hospitals prioritize durable, cost-effective instrumentation supported by responsive field clinical sales specialists and reliable inventory consignment programs.
West
The West is positioned as the fastest-growing endourology devices market in the United States, generating USD 0.52 billion in 2023, USD 0.57 billion in 2024, USD 0.62 billion in 2025, and USD 0.68 billion in 2026. By 2032, Western market value will reach approximately USD 1.14 billion, recording a nation-leading CAGR of 8.99% between 2027 and 2032.
The dynamic growth profile of the West is driven by rapid population expansion, early and aggressive clinical adoption of disruptive surgical technologies, high penetration of outpatient surgical centers, and a highly competitive private healthcare delivery landscape. Western health systems and independent ambulatory centers historically lead the nation in adopting single-use endoscopic platforms, recognizing the operational efficiencies of completely offloading scope reprocessing and maintenance. Furthermore, the region exhibits high health consciousness, strong commercial insurance reimbursement profiles, and rapid regulatory clearance pathways for progressive surgical techniques.
California dominates the Western region and ranks as the largest individual state market in the nation alongside Texas, generating approximately USD 0.41 billion in endourology device sales in 2025. With a diverse population approaching 39 million, California possesses an immense absolute volume of stone formers, despite possessing a lower age-adjusted stone prevalence than the southeastern states. The state’s immense healthcare market is anchored by world-renowned academic medical centers in Los Angeles, the San Francisco Bay Area, San Diego, and Sacramento, which serve as pioneering trial sites for artificial intelligence-integrated endourology suites, micro-PCNL systems, and advanced pressure-regulated access sheaths. Moreover, California boasts the highest concentration of licensed ambulatory surgery centers in the United States, creating an enormous commercial engine for single-use flexible ureteroscopes, compact thulium fiber lasers, and high-performance nitinol stone extractors.
Washington and Arizona represent key pillars of Western market expansion. Washington recorded approximately USD 0.08 billion in endourology device demand in 2025, with Seattle serving as the primary tertiary referral and medical technology hub for the entire Pacific Northwest. Washington’s highly consolidated integrated delivery networks are aggressive adopters of standardization agreements, contracting enterprise-wide with medical device manufacturers to deploy uniform single-use scope and consumable portfolios across multi-hospital networks. Arizona represents one of the fastest-growing state markets in the country, generating USD 0.07 billion in 2025. Fueled by rapid general population growth and a booming retiree demographic in Phoenix and Tucson, combined with an arid desert climate that drives acute dehydration and stone crystallization, Arizona exhibits high-intensity utilization of lithotripsy systems, laser fibers, and benign prostatic hyperplasia resection devices.
Colorado, Utah, Oregon, and Nevada provide critical incremental volume. Colorado’s active, health-conscious population generates steady surgical demand across expanding surgical centers in Denver, Colorado Springs, and Boulder. Utah stands out as an innovative healthcare market, where major healthcare systems implement disciplined, value-based procurement strategies that heavily reward single-use scopes for their proven ability to eliminate infection risks and lower overall procedural cycle times. Nevada, particularly the Las Vegas metropolitan area, experiences rapid population growth that is driving substantial capital hospital investment and high-volume ambulatory urology facility construction.
Midwest
The Midwest represents a deeply established, highly stable, and clinically substantial endourology market, generating USD 0.41 billion in 2023, USD 0.44 billion in 2024, USD 0.47 billion in 2025, and USD 0.50 billion in 2026. By 2032, the Midwestern market is projected to reach approximately USD 0.77 billion, advancing at a steady CAGR of 7.46% during the forecast period.
The Midwestern market is characterized by mature, highly consolidated healthcare systems, significant industrial manufacturing expertise, an aging demographic base, and a severe chronic disease profile. While the Midwest does not experience the extreme climate-driven stone formation seen in the South, it possesses a substantial stone disease burden rooted in high rates of obesity, metabolic syndrome, and dietary factors across both metropolitan centers and extensive rural communities. The region is notable for high procedural rates of percutaneous nephrolithotomy, as rural agricultural populations frequently delay seeking medical intervention for flank discomfort, presenting to tertiary medical centers with advanced, multi-centimeter staghorn calculi that demand aggressive percutaneous intervention rather than simple outpatient ureteroscopy.
Illinois stands as the economic anchor of the Midwest, generating approximately USD 0.18 billion in endourology device sales in 2025. Chicago represents one of the dense medical corridors in North America, housing prestigious academic health systems, extensive urology residency programs, and large community hospital networks. These institutions perform massive volumes of retrograde intrarenal surgery, complex percutaneous stone extractions, and advanced oncological transurethral resections. Illinois hospital networks are characterized by disciplined, committee-driven capital procurement, where device vendors must prove quantifiable reductions in operating room turnover and long-term instrument maintenance costs before securing formulary placement.
Ohio represents the second largest Midwestern state market, generating approximately USD 0.13 billion in endourology device revenue in 2025. With an aging industrial population, Ohio records elevated rates of benign prostatic hyperplasia and bladder cancer, driving substantial, year-round demand for bipolar resectoscopes, laser enucleation platforms, and diagnostic cystoscopy equipment. Prominent healthcare systems in Cleveland, Columbus, and Cincinnati manage vast patient networks, serving as key centers for endourological clinical trials and large-scale device evaluations.
Michigan accounts for approximately USD 0.10 billion in market value in 2025, with major medical centers across Detroit, Ann Arbor, and Grand Rapids supporting sophisticated stone and urologic oncology programs. Indiana, Wisconsin, Minnesota, and Missouri contribute substantial, consistent device utilization. Minnesota is uniquely strategic as a global hub for medical device engineering and clinical research, housing legendary medical institutions that heavily influence national surgical practice patterns and clinical device guidelines.
The procurement environment in the Midwest places immense emphasis on total cost of ownership, comprehensive clinical education, and robust field service support. Community hospitals and regional healthcare systems facing strict capital budget constraints frequently leverage collective group purchasing organization agreements to negotiate aggressive volume discounts across high-volume consumable lines such as double-J stents, guidewires, and access sheaths.
Northeast
The Northeast represents a mature, high-value endourology devices market, generating USD 0.23 billion in 2023, USD 0.24 billion in 2024, USD 0.26 billion in 2025, and USD 0.28 billion in 2026. By 2032, the Northeastern market is forecast to reach approximately USD 0.39 billion, growing at a CAGR of 5.68% from 2027 to 2032.
Although the Northeast is the smallest geographic region by total market size, it carries disproportionate clinical and strategic weight across the domestic medical device landscape. The region boasts the highest density of academic medical centers, tertiary referral hospitals, Ivy League medical schools, and specialized cancer institutes in the world. Consequently, the Northeast serves as the primary national testing ground for advanced endourological technologies, leading the nation in early clinical evaluations of blue-light photodynamic diagnostic cystoscopy for bladder cancer, smart sensor-integrated access sheaths, and robotic-assisted retrograde intrarenal surgery platforms. While population growth in the Northeast is modest compared to the South and West, the region’s older demographic profile ensures robust baseline demand for urologic oncology instrumentation and benign prostatic hyperplasia interventions.
New York commands the largest share of the Northeastern market, generating approximately USD 0.29 billion in endourology device revenue in 2025. The immense metropolitan healthcare ecosystem of New York City, combined with major health systems in Long Island, Westchester, and upstate urban centers, creates extraordinary demand for premium endourological capital and consumables. New York hospital operating rooms handle some of the most medically complex patients in the nation, requiring cutting-edge dual-pulse holmium and thulium fiber laser systems, single-use flexible digital ureteroscopes, and advanced hemodynamic monitoring equipment to ensure patient safety during prolonged lithotripsy procedures.
Massachusetts is internationally recognized as a pinnacle of surgical innovation and medical device research, generating roughly USD 0.08 billion in endourology device sales in 2025. Boston-area academic medical centers and specialized urology departments are world-leading centers of excellence for minimally invasive stone surgery and urologic oncology. Clinical faculty in Massachusetts frequently author the peer-reviewed clinical trials and surgical guidelines that drive nationwide device adoption. Device manufacturers heavily target Massachusetts institutions for clinical validation studies, beta-testing of next-generation digital sensors, and health-economic research validating the cost-effectiveness of single-use endoscopes.
Pennsylvania represents another critical market pillar, generating approximately USD 0.09 billion in 2025, anchored by massive health networks across Philadelphia and Pittsburgh that manage high volumes of stone disease and bladder cancer. New Jersey, Connecticut, Rhode Island, Maine, New Hampshire, and Vermont provide additional, highly stable demand. Healthcare procurement in the Northeast is characterized by rigorous evidence-based assessment. Hospital value-analysis committees require exhaustive clinical data demonstrating superior stone-free rates, reduced operative times, and lower readmission rates before approving novel capital platforms or premium-priced single-use consumables.
Key Market Players
The U.S. endourology devices competitive landscape is characterized by high consolidation within capital imaging towers, laser generators, and premium flexible endoscopes, coexisting with targeted fragmentation across specialized accessories, disposables, and procedural consumables.
Some of the highly relevant players operating in the U.S. endourology devices industry are:
Boston Scientific Corporation
Olympus Corporation
Cook Medical
Karl Storz Endoscopy-America Inc.
Richard Wolf Medical Instruments Corp.
Medtronic plc
Teleflex Incorporated
Coloplast Corp.
BD (Becton, Dickinson and Company)
Stryker Corporation
Siemens Healthineers
Lumenis Be Ltd.
Dornier MedTech
Intuitive Surgical, Inc.
Rocamed
Boston Scientific Corporation stands as the market-defining leader within the U.S. endourology ecosystem, commanding unmatched market share across single-use flexible ureteroscopes, stone retrieval baskets, access sheaths, and laser lithotripsy systems. The company revolutionized the global endourology landscape with the commercial launch of the LithoVue single-use digital flexible ureteroscope, establishing the clinical and economic blueprint for disposable endoscopy. Boston Scientific maintains an expansive, vertically integrated stone management portfolio, bolstered by the acquisition of Lumenis’ surgical business, which integrated world-class high-power holmium:YAG laser platforms and proprietary Moses pulse-modulation technology into its commercial channel. The company’s pervasive presence across domestic group purchasing organization contracts and comprehensive consumable bundles makes it an indispensable partner for both high-volume hospital networks and outpatient surgery centers.
Olympus Corporation represents the gold standard in optical engineering, surgical visualization, and endourological capital infrastructure. Holding commanding market positions in rigid cystoscopy, resectoscopy, and reusable digital flexible ureteroscopes, Olympus anchors thousands of hospital urology suites across the United States. The company’s VISERA ELITE imaging towers provide pristine visual clarity, narrow-band imaging for enhanced urothelial carcinoma detection, and seamless integration with electrosurgical generators. Olympus has aggressively defended its leadership by introducing its own single-use flexible ureteroscopes and launching high-frequency thulium fiber laser systems designed to challenge legacy holmium dominance. The company’s deeply entrenched service infrastructure, long-term hospital maintenance agreements, and strong brand loyalty among urologic surgeons secure its foundational market position.
Cook Medical is an established global pioneer in minimally invasive medical devices, commanding immense market share in the accessories and consumables sector. The company’s endourology portfolio is anchored by industry-standard guidewires, hydrophilic ureteral access sheaths, multi-wire nitinol stone retrieval baskets, and diverse double-J stent architectures. Cook Medical maintains deep clinical relationships with academic endourologists, continually refining consumable designs to optimize torque control, pushability, and atraumatic mucosal navigation. The company’s focus on biomaterials science, particularly encrustation-resistant stent polymers and ultra-low-profile stone extractors, ensures highly profitable, high-volume recurring revenue across every domestic surgical channel.
Karl Storz Endoscopy-America Inc. is globally renowned for German optical craftsmanship, precision mechanical engineering, and durable surgical instrumentation. Karl Storz maintains a dominant presence in hospital operating rooms with its comprehensive line of rigid and semi-rigid ureteroscopes, diagnostic and operative cystoscopes, and high-performance nephroscopes for percutaneous stone surgery. The company’s IMAGE1 S modular camera platform allows seamless switching between rigid and flexible endoscopes while integrating advanced visualization modes like blue-light cystoscopy for early bladder cancer diagnosis. Karl Storz continues to expand its hybrid portfolio, offering high-durability reusable scopes alongside specialized single-use video endoscopes to serve evolving institutional procurement preferences.
Richard Wolf Medical Instruments Corp. represents another premier German endoscopic engineering powerhouse with substantial U.S. market presence. Richard Wolf is celebrated for its robust, long-lasting rigid endoscopes, miniature nephroscopes, and innovative stone fragmentation platforms. The company pioneered the development of specialized “Mini-PCNL” systems that allow percutaneous stone removal through ultra-small access sheaths, significantly reducing renal parenchymal trauma. Richard Wolf also competes strongly in piezoelectric extracorporeal shock wave lithotripsy and integrated operating room video management, maintaining strong loyalty among high-volume academic and hospital endourologists who demand mechanical perfection and longevity.
Medtronic plc maintains a strategic presence in the broader urological device landscape, providing advanced electrosurgical generators, vessel-sealing instruments, and fluid management systems utilized during complex transurethral and endourological interventions. While primarily recognized for its massive cardiac and surgical portfolios, Medtronic’s precision energy delivery platforms, advanced suction-irrigation technologies, and vast enterprise-level hospital contracting networks make it a prominent player in high-acuity surgical suites where multidisciplinary capital equipment is procured.
Teleflex Incorporated is a formidable competitor in specialized urological access, drainage, and interventional devices. Through its Arrow and Rüsch brand lines, Teleflex supplies immense domestic volumes of Foley catheters, specialized ureteral stents, guidewires, and percutaneous nephrostomy sets. The company’s urology portfolio emphasizes clinical safety, infection reduction, and workflow efficiency, maintaining pervasive distribution across U.S. hospitals, outpatient clinics, and long-term care networks. Teleflex leverages high-volume manufacturing and bundled supply agreements to secure dominant positions in baseline consumable procurement.
Coloplast Corp. has established itself as a major, high-growth contender in the U.S. endourology market through its dedicated Interventional Urology division. The company provides a comprehensive and technologically advanced line of stone management accessories, including hydrophilic guidewires, stone retrieval baskets, ureteral access sheaths, and double-J stents. Coloplast has accelerated its competitive impact by aggressively expanding into single-use digital flexible ureteroscopy, providing high-definition disposable scopes that directly challenge incumbent market leaders. The company’s agile commercial strategy, highly responsive customer service, and competitive pricing models have made it a favored partner for fast-growing ambulatory surgery centers.
BD (Becton, Dickinson and Company) commands vast market presence across diagnostic and interventional urology, primarily through its C.R. Bard legacy portfolio. BD is an absolute volume leader in urological drainage, continuous-flow irrigation manifolds, biopsy instrumentation, and post-operative stenting. The company’s expansive distribution channels, ubiquitous presence in hospital supply chains, and master group purchasing organization agreements ensure that its stents, guidewires, and disposable accessories are utilized in thousands of endourological cases daily across the United States.
Stryker Corporation brings immense surgical visualization, fluid management, and operating room integration expertise to the endourology space. Stryker’s high-definition and 4K surgical camera platforms, advanced LED light sources, and wireless operating room data networks are deployed extensively across hospital urology suites and ambulatory surgery centers. Stryker continues to innovate in ergonomic surgical handpieces, smart fluid management pumps, and smoke evacuation systems, focusing on streamlining perioperative efficiency and reducing surgeon fatigue during prolonged endoscopic interventions.
Siemens Healthineers is a dominant provider of high-acuity mobile C-arm fluoroscopy systems, interventional radiography suites, and dedicated urological examination tables. Endourological procedures—particularly retrograde pyelography, ureteroscopy, and percutaneous nephrolithotomy—depend entirely on real-time, low-dose fluoroscopic imaging to guide access sheaths, localize stone fragments, and confirm correct stent positioning. Siemens Healthineers provides advanced flat-panel detector C-arms that deliver exceptional radiopaque detail with minimal radiation scatter, anchoring capital equipment procurement across hospital endourology suites.
Lumenis Be Ltd., operating within the Boston Scientific surgical ecosystem, represents the historic and technological vanguard of medical laser innovation. Lumenis pioneered the clinical adoption of holmium:YAG lasers in endourology and transformed surgical practice with its proprietary Moses technology. This patented pulse-modulation platform fundamentally altered laser-tissue and laser-fluid interactions, eliminating stone retropulsion and accelerating vaporization efficiency for both stone lithotripsy and prostate enucleation. Lumenis platforms serve as the clinical benchmark against which all competitive laser technologies are measured.
Dornier MedTech is an iconic pioneer in the lithotripsy industry, having developed the world’s first commercial extracorporeal shock wave lithotripter. The company maintains an authoritative position in shock wave systems while expanding its footprint across advanced holmium:YAG and thulium fiber laser generators, specialty laser fibers, and integrated urological imaging tables. Dornier combines deep engineering heritage with modern photonic innovation, offering versatile lithotripsy platforms that support both hospital operating rooms and high-throughput outpatient stone centers.
Intuitive Surgical, Inc., while primarily renowned for its da Vinci robotic surgical systems, interacts strategically with the endourology sector. Complex stone disease, ureteral reconstructive surgery (such as robotic pyeloplasty for pelviureteric junction obstruction), and upper tract urothelial carcinoma resections frequently involve hybrid workflows that integrate robotic visualization with concurrent retrograde or antegrade endourological access. Intuitive continues to invest in advanced digital imaging, flexible robotic instrument architectures, and digital ecosystem integration that will interface closely with future endourological platforms.
Rocamed is a specialized, fast-growing interventional urology company that has established a dedicated presence in the U.S. market through innovative stone management solutions. The company specializes in precision-engineered nitinol stone retrieval baskets, flexible ureteroscopy accessories, anti-retropulsion devices, and specialized retrieval forceps. Rocamed differentiates itself through ergonomic, physician-centric designs that optimize tactile feedback and allow delicate caliceal manipulation, capturing market share across discerning academic and private urology practices.
Recent Developments
The U.S. endourology devices market has experienced profound structural, technological, and regulatory milestones since 2024 that are actively reshaping surgical practice and competitive dynamics.
One of the most consequential clinical developments has been the broad-scale commercial validation and institutional adoption of thulium fiber laser platforms. Throughout 2025 and 2026, major academic medical centers and ambulatory surgery chains completed comprehensive comparative evaluations between traditional high-power holmium:YAG systems and novel thulium fiber platforms. The published findings confirmed that thulium fiber lasers achieve superior stone-dusting rates, produce smaller residual fragment sizes, and virtually eliminate retropulsion, all while operating through thinner, highly flexible 150-micron fibers that do not compromise endoscope deflection. Consequently, capital procurement shifted heavily toward thulium systems, sparking a major equipment replacement cycle across both inpatient hospitals and high-volume ambulatory facilities.
The single-use flexible ureteroscope sector experienced critical technological breakthroughs during late 2025 and 2026. Leading manufacturers secured regulatory clearances for next-generation single-use digital ureteroscopes featuring embedded, distal micro-sensors that continuously monitor intrarenal fluid pressure during laser lithotripsy. These smart disposable scopes interface seamlessly with automated aspiration consoles, allowing the surgical system to instantly pause irrigation and initiate active suction whenever renal pelvic pressure approaches unsafe thresholds. By integrating pressure safety directly into a single-use scope architecture, manufacturers have eliminated one of the most persistent clinical risks associated with prolonged high-flow ureteroscopic lithotripsy.
The regulatory environment overseen by the U.S. Food and Drug Administration has intensified its focus on the cleaning, disinfection, and sterilization validation of complex reusable lumened endoscopes. In 2025, the FDA issued updated, rigorous safety communications mandating that healthcare facilities strictly adhere to validated reprocessing steps for reusable cystoscopes and ureteroscopes, recommending that providers transition to single-use alternatives when reprocessing cannot be consistently guaranteed. This heightened regulatory oversight, combined with the rising labor costs of central sterile processing technicians, has catalyzed hospital value-analysis committees to accelerate their transition from reusable flexible scopes to disposable contracts.
Strategic mergers, acquisitions, and commercial partnerships have simultaneously reshaped the competitive landscape. Medical device conglomerates have actively acquired specialized medtech startups focused on artificial intelligence video analysis, biodegradable ureteral biomaterials, and miniaturized suction access sheaths. Furthermore, leading laser manufacturers have forged exclusive commercial agreements with single-use scope makers to offer bundled capital-and-disposable packages, effectively locking in long-term facility accounts and presenting formidable competitive barriers to standalone device vendors.
Hospital and ambulatory procurement models have matured into sophisticated enterprise contracting structures. Health systems are increasingly rejecting transactional, piecemeal device purchases in favor of comprehensive cost-per-procedure agreements. Under these innovative frameworks, the medical device manufacturer provides the capital laser generator, video towers, and fluid management consoles with zero upfront capital acquisition expense, in exchange for a committed multi-year contract where the hospital purchases guaranteed annual volumes of single-use digital scopes, laser fibers, access sheaths, baskets, and stents. This financial model lowers the barrier to entry for advanced technology adoption while securing highly predictable, multi-year recurring revenue streams for device manufacturers.
Conclusion
The U.S. Endourology Devices Market Size & Share is positioned to expand from USD 2.70 billion in 2026 to approximately USD 4.35 billion by 2032, supported by an 8.27% CAGR from 2027 to 2032. Historical market development from approximately USD 2.15 billion in 2023, USD 2.31 billion in 2024, and USD 2.49 billion in 2025 demonstrates the remarkable structural resilience and procedure-driven momentum of this surgical domain.
The fundamental growth thesis for the U.S. endourology market extends far beyond simple demographic aging or baseline population expansion. The market is undergoing a profound technological and economic transformation characterized by the permanent replacement of reusable flexible scopes with single-use digital architectures, the rapid transition from legacy fragmentation to high-frequency laser dusting, the critical integration of real-time intrarenal pressure monitoring, and the ongoing migration of procedural volume into efficient ambulatory surgery centers. While hospitals and integrated health systems will remain the foundational spenders on high-acuity capital infrastructure, percutaneous platforms, and complex oncological resections, ambulatory surgery centers will capture the vast majority of incremental procedural growth.
The most lucrative and commercially attractive market segments through 2032 will center on single-use digital flexible ureteroscopes, advanced thulium fiber laser systems, sensor-integrated suction ureteral access sheaths, zero-tip nitinol stone retrieval baskets, and biocompatible encrustation-resistant ureteral stents. Urolithiasis will maintain its undisputed position as the primary volume and revenue engine, driven by climatological warming and persistent metabolic disease trends. Benign prostatic hyperplasia will provide an expansive, demographically protected foundation for laser enucleation and resection instrumentation, while non-muscle invasive bladder cancer ensures non-discretionary, lifelong surveillance cystoscopy demand.
Geographically, the South will remain the dominant commercial market in terms of absolute procedural volume and revenue generation, propelled by the enduring presence of the American “Stone Belt,” massive population in-migration, and dense retiree cohorts across Texas and Florida. The West will record the nation’s fastest expansion, driven by progressive technology adoption, high ambulatory surgery center density, and aggressive utilization of single-use platforms in California, Washington, and Arizona. The Midwest will continue to provide stable, high-volume procedural demand anchored by consolidated health networks managing advanced stone burdens, while the Northeast will maintain intense, high-value demand centered around prestigious academic medical institutions and advanced surgical oncological adoption.
For medical device executives, institutional investors, group purchasing organizations, and surgical leadership, the critical strategic imperative is clear. Competitive success in the U.S. endourology devices market no longer depends on manufacturing isolated, commoditized instruments. Commercial supremacy belongs to companies that command the complete, integrated procedural pathway—seamlessly unifying digital chip-on-the-tip optics, precision laser dusting, intelligent intrarenal pressure safety, and high-performance consumables into value-based, predictable cost-per-procedure solutions that satisfy the clinical demands of urologic surgeons and the financial mandates of modern healthcare administrators.